At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Abataceptdrug
Likely dose
Abatacept 125mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Open-label, Single Center Abatacept in IgG4-Related Disease 10-patient Proof-of-concept Study
In Brief
A Phase 2 clinical trial evaluating Abatacept for IgG4-related Disease. Completed, enrolled 10 participants across 1 site.
Detailed Summary
This is a Phase 2, single center, proof of concept clinical trial in subjects with active IgG4-Related Disease (IgG4-RD). Approximately 10 subjects with active IgG4-RD will be enrolled into this study. Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIgG4-related Disease
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartNov 2018
Primary CompletionApr 2020
Study CompletionNov 2020
TodayJul 2026
First PostedSep 13, 2018
Enrollment StartNov 13, 2018
Primary CompletionApr 10, 2020
Study CompletionNov 10, 2020
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 7.8 years ago
Interventions
Abataceptdrug
Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks)